期刊文献+

雷诺嗪的合成

Synthesis of Ranolazine
下载PDF
导出
摘要 目的抗心绞痛新药雷诺嗪的合成。方法以2,6-二甲基苯胺为原料,经氯乙酰化,与无水哌嗪缩合,最后与1-(2-甲氧苯氧基)-2,3-环氧丙烷(2)反应制得雷诺嗪。结果合成产物经熔点、红外光谱、核磁共振谱、质谱等确定结构,并改进了中间体1-[(2,6-二甲基苯基)甲酰胺甲基]哌嗪(4)的合成工艺,从而提高了目标产物的纯度和收率。结论本工艺路线方法简单,原料易得,易于工业化生产。 OBJECTIVE To synthesize Ranolazine,anew drug for the treatment of antianginal.METHOD Ranolazine was prepared from 2,6-dimethylaniline by chloacetylation,condensation with piperazine,at last treated with l-(2-methoxyphenoxy)-2,3-epoxypropane(2) to get Ranolazine.RESULTS The structure of Ranolazine was Characterized by the melting point,IR,IHNMR and MS.The preparative of immediate l-[(2,6-dimethylphenyl) aminocarbonylmethyl]piperazine(4) was improved,the purity and the yield of the target compound were increased.CONCLUSION The process can be easily controlled and is suitable for a scale production.
出处 《中国现代应用药学》 CAS CSCD 北大核心 2004年第S1期38-39,共2页 Chinese Journal of Modern Applied Pharmacy
关键词 雷诺嗪 抗心绞痛 药物化学 工艺改进 合成 Ranolazine antianginal medicinal chemistry process improvement synthesis
  • 相关文献

参考文献1

二级参考文献24

  • 1[1]Kantor PF, Lucien A, Kozak R,et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase[J]. Circ Res,2000,86(5):580-588.
  • 2[2]Detry JM. Clinical features of an anti-anginal drug in angina pectoris[J]. Eur Heart J, 1993, 14 (Suppl G): 18-24.
  • 3[3]Desideri A, Celegon L. Metabolic management of ischemic heart disease: clinical data with trimetazidine[J]. Am J Cardiol, 1998,82 (5A) : 50K-53K.
  • 4[4]Zhiliaev EV, Urzhumova TV, Glazunov AV, et al. Clinical aspects of trimetazidine (preductal) administration as an antianglnal drug[J]. Ter Arkh, 2000,72(8): 20-23.
  • 5[5]Marzilli M. Clinical benefits of a metabolic approach in the management of coronary patients[J]. Rev Port Cardiol, 2000,19 (Suppl 5):V25-V30.
  • 6[6]Zacharowski K, Blackburn B, Thiemermann C. Ranolazine,a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat[J]. Eur J Pharmacol, 2001,418(1-2): 105-110.
  • 7[7]Clarke B, Wyatt KM, McCormack JG. Ranolazine increases active pyruvate dehydrogenase in perfused normoxic rat hearts: evidence for an indirect mechanism[J]. J Mol Cell Cardiol, 1996,28(2): 341-350.
  • 8[8]Jain D, Dasgupta P, Hughes LO, et al. Ranolazine (RS43285): a preliminary study of a new anti-anginal agent with selective effect on ischaemic myocardium[J]. Eur J Clin Pharmacol, 1990,38(2): 111-114.
  • 9[9]Wang JX, Maruyama K, Murakami M. et al. Antianginal effects of ranolazine in various experimental models of angina[J]. Arzneimittelforschung, 1999,49(3): 193-199.
  • 10[10]Gralinski MR, Chi L, Park JL. et al. Protective effects of Ranolazine on ventricular fibrillation induced by activation of the ATP-dependentpotassiumchannel in the rabbit heart [J]. J Cardiovasc Pharmacol Ther, 1996,1(2): 141-148.

共引文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部